- Home
- GEG vs ANL Comparison
GEG vs ANL Comparison
Compare GEG & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEG
- ANL
- Stock Information
- Founded
- GEG 1994
- ANL 2004
- Country
- GEG United States
- ANL Cayman Islands
- Employees
- GEG N/A
- ANL N/A
- Industry
- GEG Computer Software: Prepackaged Software
- ANL
- Sector
- GEG Technology
- ANL
- Exchange
- GEG Nasdaq
- ANL Nasdaq
- Market Cap
- GEG 72.4M
- ANL 61.8M
- IPO Year
- GEG N/A
- ANL 2023
- Fundamental
- Price
- GEG $2.99
- ANL $1.79
- Analyst Decision
- GEG
- ANL Hold
- Analyst Count
- GEG 0
- ANL 1
- Target Price
- GEG N/A
- ANL N/A
- AVG Volume (30 Days)
- GEG 894.7K
- ANL 11.6K
- Earning Date
- GEG 11-10-2025
- ANL 09-26-2025
- Dividend Yield
- GEG N/A
- ANL N/A
- EPS Growth
- GEG N/A
- ANL N/A
- EPS
- GEG 0.38
- ANL N/A
- Revenue
- GEG $16,315,999.00
- ANL N/A
- Revenue This Year
- GEG N/A
- ANL N/A
- Revenue Next Year
- GEG N/A
- ANL N/A
- P/E Ratio
- GEG $7.47
- ANL N/A
- Revenue Growth
- GEG N/A
- ANL N/A
- 52 Week Low
- GEG $1.70
- ANL $1.10
- 52 Week High
- GEG $3.51
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- GEG 64.49
- ANL 58.26
- Support Level
- GEG $2.58
- ANL $1.65
- Resistance Level
- GEG $2.99
- ANL $1.91
- Average True Range (ATR)
- GEG 0.25
- ANL 0.10
- MACD
- GEG 0.01
- ANL 0.00
- Stochastic Oscillator
- GEG 49.80
- ANL 51.19
About GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.